Core Viewpoint - Huaxi Biological, a leading hyaluronic acid company, continues to face pressure on its performance, with significant declines in revenue and net profit in the first half of 2025 [1] Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.261 billion yuan and a net profit attributable to shareholders of 221 million yuan, representing year-on-year declines of 19.57% and 35.38% respectively [1] - In the second quarter, the company's revenue was 1.183 billion yuan, down nearly 20% year-on-year [2] - The skincare innovation business, a key revenue driver, generated 912 million yuan, experiencing a decline of over 30% year-on-year [2] Industry Comparison - The company's performance significantly lags behind the industry, with China's cosmetic retail sales reaching 229.1 billion yuan in the first half of 2025, a year-on-year growth of 2.9% [3] - Competitors such as Proya and Shuiyang reported nearly 10% year-on-year revenue growth during the same period [3] Cost Management - Huaxi Biological has significantly reduced its sales expenses, which amounted to 808 million yuan in the first half of 2025, down 31.44% year-on-year, accounting for 35.74% of revenue, a decrease of over 6 percentage points [3] - The company has ceased price promotion campaigns on various platforms, aiming to restructure its brand's technical foundation for better customer acquisition models [3] Business Strategy - The company is adopting a "price-for-volume" strategy to boost sales of its medical beauty products, with medical product revenue at 467 million yuan, down 1.8% year-on-year, while sales of three types of medical devices increased by 20% [3] - Huaxi Biological plans to optimize its product structure and channel layout to adapt to market changes [4] Brand Development - The medical beauty brands "Run Bai Yan" and "Run Zhi" have been launched on the Meituan medical beauty platform to enhance user reach [6] - The chairman of Huaxi Biological, Zhao Yan, has returned to frontline operations to boost performance, although the effectiveness of these reforms may take more time to manifest [6]
华熙生物暂时不愿促销投流了